These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18228568)

  • 1. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.
    Goetz CG; Wuu J; McDermott MP; Adler CH; Fahn S; Freed CR; Hauser RA; Olanow WC; Shoulson I; Tandon PK; ; Leurgans S
    Mov Disord; 2008 Apr; 23(5):690-9. PubMed ID: 18228568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa response in early Parkinson's disease.
    Hauser RA; Auinger P; Oakes D;
    Mov Disord; 2009 Dec; 24(16):2328-36. PubMed ID: 19908302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D; Oliver-Willwong R
    Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease.
    Goetz CG; Leurgans S; Raman R;
    Mov Disord; 2002 Mar; 17(2):283-8. PubMed ID: 11921113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entacapone in the treatment of Parkinson's disease.
    Schrag A
    Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of minimal clinically important change in early and advanced Parkinson's disease.
    Hauser RA; Auinger P;
    Mov Disord; 2011 Apr; 26(5):813-8. PubMed ID: 21437987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of the placebo response in clinical trials on Parkinson's disease: A meta-analysis.
    Shin CW; Hahn S; Park BJ; Kim JM; Park EO; Jeon B
    Parkinsonism Relat Disord; 2016 Aug; 29():83-9. PubMed ID: 27237106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate placebo effect in Parkinson's disease--is the subjective relief accompanied by objective improvement?
    Fregni F; Boggio PS; Bermpohl F; Maia F; Rigonatti SP; Barbosa ER; Pascual-Leone A
    Eur Neurol; 2006; 56(4):222-9. PubMed ID: 17057382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo influences on dyskinesia in Parkinson's disease.
    Goetz CG; Laska E; Hicking C; Damier P; Müller T; Nutt J; Warren Olanow C; Rascol O; Russ H
    Mov Disord; 2008 Apr; 23(5):700-7. PubMed ID: 18175337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S; Factor SA; Molho ES; Feustel PJ
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Objective changes in motor function during placebo treatment in PD.
    Goetz CG; Leurgans S; Raman R; Stebbins GT
    Neurology; 2000 Feb; 54(3):710-4. PubMed ID: 10680808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.